Chairpersons' introduction
Alexander Drzezga, Cologne / Germany
Yoshimi Anzai, Salt Lake City / United States
1. To describe the changing role of anatomical and molecular imaging for patients with neurodegenerative disorders, and the shift from nosological diagnosis to a biomarker-defined diagnosis.
2. To identify newest developments in PET tracers for specific neurodegenerative diseases.
3. To explain the role of advances in AI and imaging hardware in the diagnosis of neurodegenerative disease.